Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ROKIT Healthcare

Request full access

Organ regeneration platform using its proprietary 3D bio-fabrication technologies

Seoul, South KoreaFounded 2012Biotech & Life Sciences

About ROKIT Healthcare

ROKIT Healthcare, established in 2012 by founder and CEO Seok-Hwan You, is a South Korean biotechnology firm specializing in regenerative medicine. You, who previously served as an executive at Daewoo Motor and CEO of Celltrion Healthcare, founded the company with a vision to shift from imprecise medical treatments to personalized, regenerative solutions. The company has secured approximately $30 million in funding over three rounds, including a Series C in July 2020 led by DRADS Capital, and has since gone public on the KOSDAQ exchange.

The core of ROKIT Healthcare's business is its AI Hyper-Personalized Organ Regeneration Platform. This platform integrates AI-driven diagnostics with proprietary 4D bioprinting technology to create patient-specific therapies for tissue and organ regeneration. The primary business model involves providing its flagship "Dr. INVIVO" 4D bioprinters to hospitals and clinics, often free of charge, and generating revenue through the sale of single-use, patient-specific kits for each treatment. The process uses a patient's own (autologous) tissues, such as abdominal fat, to create a 'bio-ink', which is then used to print a regenerative patch. Because the material is sourced from the patient, the risk of immune rejection is eliminated.

The company's initial and most commercialized application is a skin regeneration platform for treating diabetic foot ulcers (DFU), a condition that can otherwise lead to amputation. This treatment has been successfully used in clinical trials and is being commercialized in numerous countries. Building on this success, ROKIT is expanding its platform to address other chronic conditions, including cartilage regeneration for osteoarthritis and a treatment for chronic kidney disease, which is currently in the clinical stage. These applications similarly use autologous tissue to create customized regenerative patches.

Beyond organ regeneration, ROKIT operates through two additional divisions. ROKIT America focuses on the anti-aging market, developing and selling bio-supplement products, most notably Nicotinamide Mononucleotide (NMN) supplements, which are designed to boost NAD+ levels to support cellular health and longevity. ROKIT Genomics offers advanced single-cell RNA sequencing (scRNA-seq) analysis as a service to researchers, government agencies, and institutions, providing support from experimental design to data analysis in fields like oncology and immunology.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2025
Employees
70
Open positions
None listed
Dealroom signal
52.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Regenerative Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITY✓Other financing Apr 2026 $25M — MIGUAE ↗
POST IPO EQUITY✓Other financing Mar 2026 $52M — GVA Capital · Oasis Management · Milestone Asset Management · NH Investment & Securities ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

ROKIT Healthcare website traffic

Latest recorded traffic for ROKIT Healthcare is 17K monthly website visits, up 0% over the last three months. ROKIT Healthcare's team grew 12.9% over the past year.

Latest monthly visits17K 3-month web change0% 1-year team growth+12.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

ROKIT Healthcare in the Seoul ecosystem

Live from Dealroom

The ROKIT Healthcare office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Korea Venture Investment Corporation
  • Hana Financial Investment
  • DS Investment Solutions
  • Ascendo Ventures
  • Shinhan Financial Group
  • Tion

Series B and later9 investors entered at this stage

  • DRADS Capital
  • Genaxis
  • GVA Capital
  • Oasis Management
  • Milestone Asset Management
  • NH Investment & Securities
  • PAG
  • Weiss Asset Management
  • MIGUAE

Other known investors1 additional known investor

  • Nextrans Korea
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇰🇷 South Korea88.1%
🇺🇸 United States9.5%
🇨🇦 Canada2.4%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ROKIT Healthcare on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ROKIT Healthcare’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.